Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

UniQure NV (QURE) Common Stock EUR0.05

Sell:$33.77 Buy:$33.86 Change: $2.15 (5.99%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Sell:$33.77
Buy:$33.86
Change: $2.15 (5.99%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Sell:$33.77
Buy:$33.86
Change: $2.15 (5.99%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Contact details

Address:
Paasheuvelweg 25a
AMSTERDAM
1105 BP
Netherlands
Telephone:
+31 (20) 2406000
Website:
www.uniqure.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
QURE
ISIN:
NL0010696654
Market cap:
$1.75 billion
Shares in issue:
46.12 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Matthew Kapusta
    Chief Executive Officer, Executive Director
  • Christian Klemt
    Principal Financial Officer, General Manager - Amsterdam site
  • Ricardo Dolmetsch
    President, Research and Development
  • Pierre Caloz
    Chief Operating Officer
  • Alexander Kuta
    Executive Vice President, Operations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.